A new clinical trial for patients with unresectable cutaneous squamous cell carcinoma (cuSCC) is presently recruiting patients at the Cross Cancer Institute in Edmonton, Alberta. While Avelumab, the drug being introduced in this trial has not yet been approved for sale or widespread use by Health Canada, permission has been granted to use the drug in this clinical trial to determine rates of tumour response prior to and after treatment, as well as the rate of progression-free survival.
To read more about this trial, click here.
No comments:
Post a Comment